GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2009

FDA Clears Novartis Medication as Initial Therapy for Blood Pressure

  • FDA approved Novartis Tekturna HCT® tablets as initial therapy for hypertensive patients likely to need multiple blood pressure medications. The drug is a single-pill combination of the direct renin inhibitor, aliskiren (Tekturna/Rasilez), and the diuretic hydrochlorothiazide (HCT).

    Tekturna HCT was first approved in the U.S. in January 2008 as a second-line treatment for high blood pressure, and in the EU in January 2009. Novartis says that it is also developing other single-pill aliskiren combinations including a combination with Diovan (valsartan) and one with amlodipine.

    The single-agent direct renin inhibitor, Tekturna, was first approved in March 2007 and is now available in over 70 countries. Most recently in July 2009 it entered Japan.

     

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?